Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
Eligible age
65+ yrs
Accepts
Women
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this study is to learn how GLP-1 receptor agonist therapy affects muscle and bone health in older females over age 65 with type 2 diabetes. The main question it aims to answer is whether or not 6 months of GLP-1 RA therapy affects muscle strength. Participants will: * Receive GLP-1 RA therapy as part of their routine clinical care * Complete muscle strength assessments (hand grip strength, Timed Up and Go test) * Provide blood samples for bone turnover markers * Undergo bone mineral density testing
Sponsor: Emory University
You may qualify if…
- ✓ Postmenopausal women aged 65 years or older
- ✓ Has type 2 diabetes
- ✓ Body Mass Index (BMI) ≥27 kg/m² to max 40kg/m2 (inclusive)
- ✓ Hemoglobin A1c \>7% within 3 months of the first visit.
- ✓ Willingness and ability to comply with all study procedures, including fasting requirements for certain visits.
- ✓ No osteoporosis confirmed on DEXA scan within 12 months
- ✓ Able to provide informed consent and participate in all study assessments
You may not qualify if…
- ✕ Patients with type 1 diabetes mellitus or other types of diabetes that are not T2D
- ✕ eGFR \<30 ml/min in the last 3 months
- ✕ Patients with a history of treatment with anti-osteoporosis agents
- ✕ Documented primary or secondary osteoporosis on a DEXA scan within the last 12 months, or are on osteoporosis therapies
- ✕ Documented presence of prosthesis or devices in the spine or hip
- ✕ Previous fragility fracture
- ✕ Males
- ✕ Moderate to severe gastroesophageal reflux disease based on patient history.
Where it's recruiting
Atlanta
Source: ClinicalTrials.gov · NCT07428746 · last updated 2026-08-03